Cimicoxib

Jump to navigation Jump to search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Cimicoxib

Articles

Most recent articles on Cimicoxib

Most cited articles on Cimicoxib

Review articles on Cimicoxib

Articles on Cimicoxib in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Cimicoxib

Images of Cimicoxib

Photos of Cimicoxib

Podcasts & MP3s on Cimicoxib

Videos on Cimicoxib

Evidence Based Medicine

Cochrane Collaboration on Cimicoxib

Bandolier on Cimicoxib

TRIP on Cimicoxib

Clinical Trials

Ongoing Trials on Cimicoxib at Clinical Trials.gov

Trial results on Cimicoxib

Clinical Trials on Cimicoxib at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Cimicoxib

NICE Guidance on Cimicoxib

NHS PRODIGY Guidance

FDA on Cimicoxib

CDC on Cimicoxib

Books

Books on Cimicoxib

News

Cimicoxib in the news

Be alerted to news on Cimicoxib

News trends on Cimicoxib

Commentary

Blogs on Cimicoxib

Definitions

Definitions of Cimicoxib

Patient Resources / Community

Patient resources on Cimicoxib

Discussion groups on Cimicoxib

Patient Handouts on Cimicoxib

Directions to Hospitals Treating Cimicoxib

Risk calculators and risk factors for Cimicoxib

Healthcare Provider Resources

Symptoms of Cimicoxib

Causes & Risk Factors for Cimicoxib

Diagnostic studies for Cimicoxib

Treatment of Cimicoxib

Continuing Medical Education (CME)

CME Programs on Cimicoxib

International

Cimicoxib en Espanol

Cimicoxib en Francais

Business

Cimicoxib in the Marketplace

Patents on Cimicoxib

Experimental / Informatics

List of terms related to Cimicoxib

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Cimicoxib (UR-8880 trade name Cimalgex) is a non-steroidal anti-inflammatory drug (NSAID) used in veterinary medicine to treat dogs for pain and inflammation associated with osteoarthritis and for the management of pain and inflammation associated with surgery.[1] It acts as a COX-2 inhibitor.

Synthesis

Cimicoxib synthesis:[2]

Reaction of the imine with tosylisocyanate in the presence of potassium carbonate leads to what may be viewed as 2+3 cycloaddition of the nitrogen analogue of a ketene to form the imidazole ring.

References

  1. "European Public Assessment Report: Cimalgex (cimicoxib)". European Medicines Agency.
  2. Template:Cite doi